Bladder cancer screening. Semin Oncol 1996 Oct;23(5):585-97
Date
10/01/1996Pubmed ID
8893869Scopus ID
2-s2.0-0029852136 (requires institutional sign-in at Scopus site) 25 CitationsAbstract
Transitional cell carcinoma of the bladder possesses several features that make it an ideal candidate for screening: metastases rarely occur before tumors invade the muscularis propria; superficial disease is treated very successfully by relatively inexpensive and nonmorbid means; this malignancy is almost never found incidentally at autopsy so that early detection cannot harm a patient; and almost all tumors cause hematuria if one tests frequently enough. When compared with a contemporary age, geography, and gender-matched unscreened population, bladder cancer screening in healthy men age 50 years and older by repeated home hematuria testing using chemical reagent strips significantly decreases bladder cancer morbidity and mortality and is cost-effective. A randomized prospective trial of bladder cancer screening in this population is recommended. Additionally, other potential means of bladder cancer screening and other target populations are discussed in this article.
Author List
Kryger JV, Messing EAuthor
John V. Kryger MD Chief, Professor in the Urologic Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorChronic Disease
Flow Cytometry
Hematuria
Humans
Male
Risk Factors
Urinary Bladder Neoplasms
